Compare Ascendis Pharma A/S (ASND) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs VanEck Video Gaming and eSports ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while VanEck Video Gaming and eSports ETF trades at $92.35. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ASND | ESPO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $122.30 |
52-Week Low | $163.32 | $85.25 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ESPO trades at $92.35, down 0.52% on the day, with a bullish technical signal driven by moving averages. The ETF's focus on video gaming and esports capitalizes on digital entertainment growth, supported by institutional accumulation. Key resistance lies near $93, with RSI levels indicating potential overbought conditions.
Outlook remains positive due to AI-driven profit potential in gaming, though high RSI suggests near-term consolidation risk. Investors benefit from exposure to a high-growth sector, but should monitor valuation metrics as financial ratios are currently undisclosed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
